Popular Articles

Provectus Pharmaceuticals Initiates New PH-10 Clinical Study For Psoriasis
Provectus Pharmaceuticals, Inc. (OTC BB: PVCT ), a development-stage oncology and dermatology biopharmaceutical company, has initiated a new Phase 2 clinical trial of PH-10 for psoriasis involving daily dosing of patients for 28 days. After reviewing safety and efficacy data from its PH-10 trial for atopic dermatitis, Provectus determined that daily dosing of patients with psoriasis trial would be an appropriate and attractive regimen. The new study supplants an earlier Phase 2 study, using twice weekly dosing for 12 weeks, which was terminated earlier in June.
generic viagra online
E-health Record To Help Ensure Better Treatment
A National e-health record promises to ensure patients have access to more expedient
News of the day
Oral Piercings Pose Potential Health Care Risks
Like clothing and hairstyles, oral piercings give teens and adults a way to express themselves. While trendy, this fashion statement poses a number of potential oral and overall health care risks. It"s also important to note that oral piercings most commonly involve the tongue, and also the lips, cheeks, uvula or a combination of sites. Oral piercings have been implicated in a number of adverse oral and systemic conditions.
Diagnostics

Information Sharing Unaffected By Embarrassing Illnesses

People with potentially "stigmatizing" medical conditions are just as likely as those with less stigmatizing illnesses to allow their personal information to be used for health research. A new study, published in the open access journal BMC Medical Ethics, found that the purpose of the research and the type of information to be collected were more important in determining patients" consent choices. In particular, they were very wary of allowing their personal information to be put to commercial use. Donald Willison, Senior Scientist with the Ontario Agency for Health Protection and Promotion, Canada, led a team of researchers who surveyed 1137 people who either had potentially stigmatizing conditions (HIV, alcoholism, chronic depression or lung cancer) or lower-stigma conditions (hypertension, breast cancer or diabetes), as well as a reference group of healthy people. They presented the subjects with a series of situations and asked them to indicate how much control they would want over the use of their personal information in each case. According to Willison, "Across scenarios, consent choice profiles were very similar for all health conditions. They were also very similar to the profile of the reference group. These findings surprised us. It may be that, across health conditions, those who were more privacy-sensitive were less inclined to participate in the study, or it may just be that, where people believe that their information will be put to constructive use, people are equally willing to allow their information to be used, regardless of their health condition." The researchers found people wanted more control in research scenarios involving profit or those that linked health information with income, education, or occupation. Focus groups were held with some of the respondents where they were asked to explain their choices. One participant form the HIV group said, "I think the simple answer is that physical tissue sample is just a piece of what you are, what you might beò€¦where the rest of the information [education, income, and employment] is more of who you are. People are more afraid of the revelation of who you are than what you are." Speaking about the results, Willison said, "Individuals should be offered some choice in use of their information for different types of health research. In some cases, like population health research, that may be limited to selectively opting-out of research projects. In other cases, like linkage of biological samples with one"s health information, the process would likely continue to require an opting in, perhaps through a broad consent for a range of uses. Just what choices would be offered would have to be determined through further engagement with the public and other stakeholders. Many questions remain, including how best to capture the opinions of those who are more privacy sensitive." Notes: Consent for use of personal information for health research: Do people with potentially stigmatizing health conditions and the general public differ in their opinions? Donald J Willison, Valerie Steeves, Cathy Charles, Lisa Schwartz, Jennifer Ranford, Gina Agarwal, Ji Cheng and Lehana Thabane BMC Medical Ethics (in press) http://www.biomedcentral.com/bmcmedethics/ Graeme Baldwin BioMed Central


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):